Patents by Inventor Ruin Moaddel

Ruin Moaddel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200360393
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine , or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-Hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Application
    Filed: July 31, 2020
    Publication date: November 19, 2020
    Inventors: IRVING W. WAINER, RUIN MOADDEL, MICHEL BERNIER, CARLOS A. ZARATE, MARC C. TORJMAN, MICHAEL E. GOLDBERG, MARY J. TANGA
  • Publication number: 20190135732
    Abstract: The disclosure provides a method for synthesizing free base forms of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal forms of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.
    Type: Application
    Filed: March 27, 2017
    Publication date: May 9, 2019
    Inventors: Craig Thomas, Carlos Zarate, Ruin Moaddel, Todd Gould, Panos Zanos, Patrick Morris
  • Publication number: 20190083420
    Abstract: Disclosed is a method of treating Psychotic Depression, Suicidal Ideation, Disruptive Mood Dysregulation Disorder, Persistent Depressive Disorder (Dysthymia), Premenstrual Dysphoric Disorder, Substance/Medication-Induced Depressive Disorder, Depressive Disorder Due to Another Medical Condition, Other Specified Depressive Disorder, Unspecified Depressive Disorder, Separation Anxiety Disorder, Selective Mutism, Specific Phobia, Social Anxiety Disorder (Social Phobia), Panic Disorder, Panic Attack (Specifier), Agoraphobia, Generalized Anxiety Disorder, Substance/Medication-Induced Anxiety Disorder, Anxiety Disorder Due to Another Medical, Other Specified Anxiety Disorder, Unspecified Anxiety Disorder, or fatigue the method including administering a pharmaceutical composition containing an effective amount of an active agent, wherein the active agent is purified (2R,6R)-hydroxynorketamine, purified (2S,6S)-hydroxynorketamine, or a combination thereof, or a pharmaceutically acceptable salt thereof, together with a
    Type: Application
    Filed: March 27, 2017
    Publication date: March 21, 2019
    Inventors: Irving Wainer, Carlos Zarate, Ruin Moaddel, Todd Gould, Panos Zanos, Craig Thomas, Patrick Morris
  • Publication number: 20180098993
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Application
    Filed: December 8, 2017
    Publication date: April 12, 2018
    Inventors: IRVING W. WAINER, RUIN MOADDEL, MICHEL BERNIER, CARLOS A. ZARATE, MARC C. TORJMAN, MICHAEL E. GOLDBERG, MARY J. TANGA
  • Patent number: 9867830
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 16, 2018
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH, COOPER HEALTH SYSTEM, SRI INTERNATIONAL
    Inventors: Irving W. Wainer, Ruin Moaddel, Michel Bernier, Carlos A. Zarate, Marc C. Torjman, Michael E. Goldberg, Mary J. Tanga
  • Patent number: 9650352
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: May 16, 2017
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, COOPER HEALTH SYSTEM, SRI INTERNATIONAL
    Inventors: Irving W. Wainer, Ruin Moaddel, Michel Bernier, Carlos A. Zarate, Marc C. Torjman, Michael E. Goldberg, Mary J. Tanga
  • Publication number: 20170049780
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Application
    Filed: November 2, 2016
    Publication date: February 23, 2017
    Inventors: IRVING W. WAINER, RUIN MOADDEL, MICHEL BERNIER, CARLOS A. ZARATE, MARC C. TORJMAN, MICHAEL E. GOLDBERG, MARY J. TANGA
  • Publication number: 20140296241
    Abstract: The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite. (2R,6R)-hydroxynorketamine The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain disorder (CRPS) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.
    Type: Application
    Filed: October 15, 2012
    Publication date: October 2, 2014
    Inventors: Irving W. Wainer, Ruin Moaddel, Michel Bernier, Carlos A. Zarate, Marc C. Torjman, Michael E. Goldberg, Mary J. Tanga
  • Patent number: 7749984
    Abstract: A computer readable medium holding data of a molecular model of a ligand-gated ion channel receptor and/or a computer system for modeling said receptor are provided by the instant invention. The molecular model can be used to design novel compounds having activity as non-competitive inhibitors of the ion channel. A preferred embodiment of the invention relates to nicotinic acetylcholine receptors. Compounds having activity as non-competitive inhibitors of ligand-gated ion channel receptors and methods for inhibiting the receptor and treating diseases or disorders mediated by function of the receptor are also disclosed.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: July 6, 2010
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Irving W. Wainer, Krzysztof Jozwiak, Ruin Moaddel, Sarangan Ravichandran, Jack R. Collins
  • Publication number: 20050033522
    Abstract: A computer readable medium holding data of a molecular model of a ligand-gated ion channel receptor and/or a computer system for modeling said receptor are provided by the instant invention. The molecular model can be used to design novel compounds having activity as non-competitive inhibitors of the ion channel. A preferred embodiment of the invention relates to nicotinic acetylcholine receptors. Compounds having activity as non-competitive inhibitors of ligand-gated ion channel receptors and methods for inhibiting the receptor and treating diseases or disorders mediated by function of the receptor are also disclosed.
    Type: Application
    Filed: April 9, 2004
    Publication date: February 10, 2005
    Inventors: Irving Wainer, Krzysztof Jozwiak, Ruin Moaddel, Sarangan Ravichandran, Jack Collins
  • Publication number: 20030166301
    Abstract: The present invention is directed to a chromatography device with a stationary phase containing multiple binding moieties. The binding moieties are first solubilized and then immobilized on a stationary phase to create a multiple binding moieties phase for use in a chromatography device. In an alternative to the stationary phase embodiment, a single binding moiety can be directly bonded covalently to a support within the chromatography column. Combinations of constructions involving stationary phase immobilization and direct covalent bonding can also be employed. The multiple binding moiety chromatography devices are useful in investigating interactions among different binding moieties in pharmacological studies and in drug discovery.
    Type: Application
    Filed: December 10, 2002
    Publication date: September 4, 2003
    Inventors: Irving W. Wainer, Ruin Moaddel, Jean-Francois Cloix, Gozen Ertem
  • Publication number: 20030150812
    Abstract: The present invention relates to a novel parallel throughput system that permits simultaneous screening of compounds in different modules of the system. Each module comprises a support having at least one species of protein binding moiety either immobilized through a covalent bond with the support surface to form an immobilized protein binding moiety or non-covalently immobilized in a stationary phase such that the tertiary structure of the protein in either immobilized binding moiety permits specific binding to a molecule that is bound by said protein in said immobilized binding moiety, and at least one marker molecule associated with the protein binding moiety species.
    Type: Application
    Filed: December 19, 2002
    Publication date: August 14, 2003
    Inventors: Irving Wainer, Ruin Moaddel
  • Publication number: 20030006192
    Abstract: This invention provides an immobilized G-protein coupled receptor (GPCR) on a support in a liquid chromatography system. The method of the invention provides means of evaluating the attachment of an agent to a GPCR comprising the steps of: (a) immobilizing a GPCR on an artificial membrane support in a column, (b) exposing the support with the GPCR to test the agent at varying concentrations in a liquid chromatography system, (c) eluting the test agent from the column, and (d) evaluating the elution profile of the test material from the column. Using this method, it is possible to evaluate the interaction of the test agent with the GPCR. Following elution, it is possible to directly determine molecular structure by passing the elute through other testing devices such as a mass spectrometer.
    Type: Application
    Filed: June 5, 2002
    Publication date: January 9, 2003
    Inventors: Irving Wainer, Yanxiao Zhang, Farideh Beigi, Ruin Moaddel